These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19932662)

  • 21. Tyranny of algorithms in the treatment of patients with hepatitis C.
    Rubin RA
    Hepatology; 2003 Dec; 38(6):1593-4; author reply 1594-5. PubMed ID: 14647072
    [No Abstract]   [Full Text] [Related]  

  • 22. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

  • 23. Amantadine for treatment of hepatitis C: time to say "enough is enough"?
    Piccolo P
    Dig Liver Dis; 2010 Jul; 42(7):468-9. PubMed ID: 20488769
    [No Abstract]   [Full Text] [Related]  

  • 24. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 26. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment strategy for chronic hepatitis C in Japan].
    Arase Y; Kumada H
    Nihon Rinsho; 2011 May; 69 Suppl 4():180-4. PubMed ID: 22096915
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
    Husa P; Husova L
    Bratisl Lek Listy; 2001; 102(5):248-52. PubMed ID: 11725377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of patients with normal liver aminotransferases].
    González Ballerga E; Levi D; Reggiardo V
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S50-2. PubMed ID: 20214303
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report.
    Bartalesi F; Camiciottoli G; Corti G; Maluccio NM; Biliotti E; Bartoloni A; Taliani G
    J Chemother; 2009 Feb; 21(1):110-1. PubMed ID: 19297285
    [No Abstract]   [Full Text] [Related]  

  • 32. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Andriulli A; Mangia A
    N Engl J Med; 2007 Oct; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hepatitis C: 15 years of life].
    Perez V
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S9-10. PubMed ID: 20214283
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 35. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis.
    Tsai MC; Lin MC; Hung CH
    J Formos Med Assoc; 2009 Sep; 108(9):746-50. PubMed ID: 19773215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA
    Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706
    [No Abstract]   [Full Text] [Related]  

  • 38. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Liu CH; Chen DS; Kao JH
    N Engl J Med; 2007 Oct; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
    [No Abstract]   [Full Text] [Related]  

  • 39. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
    Xie Y; Li MH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
    [No Abstract]   [Full Text] [Related]  

  • 40. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.